Dr. Richard Larivière is a professor in the Department of Medicine at Laval University, and a researcher within the Endocrinology and Nephrology axis of the CHU of Quebec Research Centre. He is also Director of Master’s and PhD programs in Clinical and Biomedical Sciences of the Faculty of Medicine at Laval University. Following his doctoral studies in Clinical Sciences (cardiovascular pharmacology) at the Université de Montréal, and postdoctoral studies in molecular endocrinology at McGill University, Dr. Larivière established himself as a professor-researcher in nephrology and hypertension at L’Hôtel-Dieu de Québec. He is an active member of the Amgen-Laval University Research Chair in Nephrology, a multidisciplinary group of fundamentalist and clinical researchers.
The main objective of Dr. Larivière’s research is to better define the mechanisms of arterial hypertension and remodeling of the blood vessel wall. More specifically, he studies the role of endothelial dysfunction, that is, factors derived from the vascular endothelium in the pathogenesis of arterial hypertension, vascular and renal damage in the case of chronic renal failure, and aging. Over the years, he has demonstrated that an imbalance in endothelial production of vasoconstrictor and vasodilator factors, as well as pro-inflammatory factors, contributes significantly to the increase of arterial pressure and rigidity by stimulating, among other things, hypertrophic remodeling and calcification of the blood vessel wall. He has also demonstrated that endothelial dysfunction can be modulated by various endocrine factors and pharmacological agents, including certain drugs. Dr. Larivière’s research uses a variety of experimental models and human tissue libraries.
10, rue McMahon
2853
Québec, Québec
Canada G1R 2J6
Latest news
Data not available
- Anderson, SarahInternsarah.anderson.3@ulaval.ca
- Vandal-Gélinas, GabrielleUndergraduate studentL'Hôtel-Dieu de Québec+1 418-525-4444, extension 16856gabrielle.vandal-gelinas.1@ulaval.cagabrielle.vandal-gelinas@crchudequebec.ulaval.ca
10 Rue Mcmahon
2852
Ville de Québec, QC
Canada G1R 3S1
Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis
Journal ArticleInt Urol Nephrol, 46 (4), 2014.
Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease
Journal ArticleClin Exp Hypertens, 36 (3), 2014.
Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study
Journal ArticleAm J Hypertens, 27 (11), 2014.
Determinants of progression of aortic stiffness in hemodialysis patients: a prospective longitudinal study
Journal ArticleHypertension, 62 (1), 2013.
Effects of tempol on endothelial and vascular dysfunctions and insulin resistance induced by a high-fat high-sucrose diet in the rat
Journal ArticleCan J Physiol Pharmacol, 91 (7), 2013.
eNOS gene delivery prevents hypertension and reduces renal failure and injury in rats with reduced renal mass
Journal ArticleNephrol Dial Transplant, 27 (6), 2012.
Neutralization of tumor necrosis factor-alpha reduces renal fibrosis and hypertension in rats with renal failure
Journal ArticleAm J Nephrol, 36 (2), 2012.
Age-related and blood pressure-independent reduction in aortic stiffness after kidney transplantation
Journal ArticleJ Hypertens, 29 (1), 2011.
Effects of TGF-beta1 on endothelial factors
Journal ArticleArch Physiol Biochem, 116 (1), 2010.
Increased ET-1 and reduced ET(B) receptor expression in uremic hypertensive rats
Journal ArticleClin Exp Hypertens, 32 (1), 2010.
Active projects
- Rôle de la dysfonction endothéliale dans le remodelage et la calcification vasculaire en insuffisance rénale chronique, from 2016-04-01 to 2025-03-31
Recently finished projects
- Accelerated CKD-related vascular calcification: Role of thiazide-type, thiazide-like and loop diuretics, from 2020-10-01 to 2023-05-31
- Proline hydroxylase inhibitors: linking HIF-1 to arterial calcification, from 2019-07-01 to 2021-09-30